Kandoset

Amlodipine and Candesartan cilexetil, the active ingredients in Kandoset, are a calcium channel blocker and an angiotensin II receptor blocker presented as an oral tablet for systemic use. They work together to reduce peripheral vascular resistance and block angiotensin‑II mediated vasoconstriction, thereby lowering elevated blood pressure in adult patients diagnosed with hypertension.

GNH USA supplies Kandoset as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across markets with reliable logistics and comprehensive documentation support.

Kandoset is used in the management of hypertension, a condition affecting the arterial pressure regulation system. - Hypertension (essential): lowers systolic and diastolic blood pressure in adults. - High blood pressure: helps achieve target blood pressure levels as part of therapy. - Cardiovascular risk reduction: contributes to decreased risk of stroke and heart attack by controlling blood pressure.

Kandoset may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Flushing: transient warmth and redness of the skin. - Fatigue: feeling unusually tired. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Renal impairment: worsening kidney function. - Myocardial infarction: rare occurrence of heart attack. - Allergic reactions: rash, itching, or anaphylaxis.

Before prescribing Kandoset, clinicians should consider several safety aspects. - Monitor blood pressure: ensure adequate control without excessive lowering. - Assess renal function: adjust therapy in patients with impaired kidneys. - Evaluate hepatic status: use caution in moderate to severe liver disease. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Review concomitant potassium‑sparing agents: risk of hyperkalaemia. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Kandoset can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase amlodipine levels. - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of renal dysfunction and hyperkalaemia. - Potassium‑sparing diuretics (e.g., spironolactone): heightened risk of hyperkalaemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Other antihypertensives: additive blood pressure lowering. - CYP3A4 inducers (e.g., rifampicin): may reduce amlodipine exposure. - Lithium: increased lithium levels. - Diuretics: may affect electrolyte balance.